23279-64-3

Usage

Uses

Used in Fragrance Industry:
4-(2-(N-Acetylamino)ethyl)acetophenone is used as a fragrance ingredient in perfumes and toiletries due to its strong smell.
Used in Pharmaceutical Industry:
4-(2-(N-Acetylamino)ethyl)acetophenone is used as a chemical intermediate in the synthesis of pharmaceuticals and organic compounds, potentially contributing to the development of new drugs and medicines.
It is important to handle this chemical carefully and follow proper safety precautions when working with it, as it may have potential health hazards if not used correctly.

InChI:InChI=1/C12H15NO2/c1-9(14)12-5-3-11(4-6-12)7-8-13-10(2)15/h3-6H,7-8H2,1-2H3,(H,13,15)

Upstream product

• 506-96-7 Acetyl bromide 
• 877-95-2 methyl-N-(benzyl-methyl)-formamide 
• 75-36-5 acetyl chloride 

Downstream Products

• 7465-13-6 4-(2-acetamidoethyl)benzoic acid 
• 416860-02-1 N-[2-(4-bromoacetyl-phenyl)-ethyl]-acetamide 
• 159417-92-2 4-<2-(acetamido)ethyl>-acetanilide 
• 1199-69-5 4-(2-aminoethyl)benzoic acid 

Relevant academic research and scientific papers

Discovery of potent and orally bioavailable heterocycle-based β3-adrenergic receptor agonists, potential therapeutics for the treatment of obesity

A novel series of heterocycle-based analogs were prepared and evaluated for their in vitro and in vivo biological activity as human β3-adrenergic receptor (AR) agonists. Several analogs demonstrated potent agonist activity at the β3-

Bita3 adrenergic receptor agonists and uses thereof

The instant invention provides β3 adrenergic receptor agonists of structural Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, wherein Ar, R, R1, R2, R3, R4, R5, R6, R7, R8, X, and Y, are as defined herein. The invention further provides intermediates useful in the preparation of the compounds of Formula (I), to combinations of the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, with anti-obesity agents; to pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, or pharmaceutical compositions comprising the compounds of Formula (I), the stereoisomers and prodrugs thereof, and the pharmaceutically acceptable salts of the compounds, stereoisomers and prodrugs, and anti-obesity agents; and methods of treating β3 adrenergic receptor-mediated diseases, conditions, or disorders in a mammal which methods comprise administering to the mammal an effective amount of a compound of Formula (I), a stereoisomer or prodrug thereof, or a pharmaceutical composition thereof; or a combination of a compound of Formula (I), a pharmaceutically acceptable salt of the compound, stereoisomer, or prodrug, and an anti-obesity agent, or a pharmaceutical composition thereof.